CD64 CAR T Cell Therapy
Phase 1, Open Label, Dose Escalation Study to Evaluate the Safety, Expansion, Persistence, and Preliminary Clinical Activity of Autologous CD64 CAR T Cells in Patients With Relapsed and/or Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (HR-MDS)
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 1
- Enrollment
- 23 patients (estimated)
- Tags
- CAR T Cell, CD64
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2213
- NCT Identifier
- NCT07347418
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.